Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 22.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 20.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 28.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Unternehmen & Branche
| Name | Merck & Co., Inc. |
|---|---|
| Ticker | MRK |
| CIK | 0000310158 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - General |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 29384C908 |
|---|---|
| ISIN | US29384C9083 |
| Typ | Common Stock |
| Marktkapitalisierung | 274,30 Mrd. USD |
| Beta | 0,28 |
| Dividendenrendite | 3,32 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 65,011,000,000 | 18,254,000,000 | 7.28 | 136,866,000,000 | 52,606,000,000 |
| 2025-09-30 | 10-Q | 17,276,000,000 | 5,785,000,000 | 2.32 | 129,546,000,000 | 51,850,000,000 |
| 2025-06-30 | 10-Q | 15,806,000,000 | 4,427,000,000 | 1.76 | 117,523,000,000 | 48,993,000,000 |
| 2025-03-31 | 10-Q | 15,529,000,000 | 5,079,000,000 | 2.01 | 115,122,000,000 | 48,335,000,000 |
| 2024-12-31 | 10-K | 64,168,000,000 | 17,117,000,000 | 6.74 | 117,106,000,000 | 46,313,000,000 |
| 2024-09-30 | 10-Q | 16,657,000,000 | 3,157,000,000 | 1.24 | 117,532,000,000 | 44,502,000,000 |
| 2024-06-30 | 10-Q | 16,112,000,000 | 5,455,000,000 | 2.14 | 112,630,000,000 | 43,582,000,000 |
| 2024-03-31 | 10-Q | 15,775,000,000 | 4,762,000,000 | 1.87 | 105,849,000,000 | 40,364,000,000 |
| 2023-12-31 | 10-K | 60,115,000,000 | 365,000,000 | 0.14 | 106,675,000,000 | 37,581,000,000 |
| 2023-09-30 | 10-Q | 15,962,000,000 | 4,745,000,000 | 1.86 | 106,727,000,000 | 41,246,000,000 |
| 2023-06-30 | 10-Q | 15,035,000,000 | -5,975,000,000 | -2.35 | 104,469,000,000 | 38,693,000,000 |
| 2023-03-31 | 10-Q | 14,487,000,000 | 2,821,000,000 | 1.11 | 107,796,000,000 | 46,834,000,000 |
| 2022-12-31 | 10-K | 59,283,000,000 | 14,519,000,000 | 5.71 | 109,160,000,000 | 45,991,000,000 |
| 2022-09-30 | 10-Q | 14,959,000,000 | 3,248,000,000 | 1.28 | 107,081,000,000 | 44,458,000,000 |
| 2022-06-30 | 10-Q | 14,593,000,000 | 3,944,000,000 | 1.55 | 107,095,000,000 | 43,243,000,000 |
| 2022-03-31 | 10-Q | 15,901,000,000 | 4,310,000,000 | 1.70 | 106,668,000,000 | 40,883,000,000 |
| 2021-12-31 | 10-K | 48,704,000,000 | 13,049,000,000 | 5.14 | 105,694,000,000 | 38,184,000,000 |
| 2021-09-30 | 10-Q | 13,154,000,000 | 4,567,000,000 | 1.80 | 93,494,000,000 | 35,794,000,000 |
| 2021-06-30 | 10-Q | 11,402,000,000 | 1,545,000,000 | 0.61 | 90,688,000,000 | 33,294,000,000 |
| 2021-03-31 | 10-Q | 10,627,000,000 | 3,179,000,000 | 1.25 | 90,847,000,000 | 26,945,000,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Merck & Co., Inc. | 2,953,894 | 0 | 2,953,894 | 23,676,196 | Neu | +100,0% | |
| SIMPLEX TRADING, LLC | 100 | 0 | 100 | 1,028 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-12 | Guindo Chirfi | Officer, Chief Marketing Officer | Open Market Sale | -10,000 | 121.46 | -1,214,562.00 | -52,0% | |
| 2026-02-10 | Li Dean Y | Officer, Executive VP & President, MRL | Open Market Sale | -10,235 | 117.52 | -1,202,843.81 | -51,5% | |
| 2026-02-09 | Zachary Jennifer | Officer, EVP, General Counsel | Open Market Sale | -25,946 | 119.15 | -3,091,522.98 | -132,4% | |
| 2026-02-09 | Zachary Jennifer | Officer, EVP, General Counsel | Open Market Sale | -38,835 | 119.15 | -4,627,275.69 | -198,1% | |
| 2026-02-09 | Zachary Jennifer | Officer, EVP, General Counsel | Open Market Sale | -56,792 | 119.15 | -6,766,891.74 | -289,8% | |
| 2026-02-09 | Guindo Chirfi | Officer, Chief Marketing Officer | Open Market Sale | -10,000 | 118.41 | -1,184,101.00 | -50,7% | |
| 2026-02-06 | Oosthuizen Johannes Jacobus | Officer, President, U.S. Market | Open Market Sale | -15,000 | 121.87 | -1,827,991.50 | -78,3% | |
| 2026-02-06 | Williams David Michael | Officer, EVP,Chief Info&Digital Officer | Open Market Sale | -5,000 | 121.91 | -609,525.00 | -26,1% | |
| 2026-02-06 | DeLuca Richard R. | Officer, EVP&Pres, Merck Animal Heallth | Open Market Sale | -37,685 | 120.92 | -4,557,024.71 | -195,1% | |
| 2026-02-05 | Guindo Chirfi | Officer, Chief Marketing Officer | Open Market Sale | -20,000 | 121.88 | -2,437,676.00 | -104,4% | |
| 2026-02-04 | Litchfield Caroline | Officer, EVP & CFO | Open Market Sale | -41,997 | 119.61 | -5,023,311.57 | -215,1% | |
| 2026-02-04 | Davis Robert M | Director, Officer, Chairman, CEO & President | Open Market Sale | -14,972 | 117.38 | -1,757,407.37 | -75,3% | |
| 2026-02-04 | Davis Robert M | Director, Officer, Chairman, CEO & President | Open Market Sale | -32,462 | 118.35 | -3,841,919.90 | -164,5% | |
| 2026-02-04 | Li Dean Y | Officer, Executive VP & President, MRL | Open Market Sale | -15,087 | 118.77 | -1,791,824.15 | -76,7% | |
| 2026-02-04 | Smart Dalton E. III | Officer, SVP Fin. - Global Controller | Open Market Sale | -2,400 | 119.68 | -287,220.00 | -12,3% | |
| 2026-02-04 | Smart Dalton E. III | Officer, SVP Fin. - Global Controller | Open Market Sale | -4,000 | 119.68 | -478,700.00 | -20,5% | |
| 2025-11-10 | Downing Cristal N | Officer, Chief Comm. & Public Afrs Ofcr | Open Market Sale | -7,085 | 87.00 | -616,395.00 | -26,4% | |
| 2025-11-03 | Williams David Michael | Officer, EVP,Chief Info&Digital Officer | Open Market Sale | -8,614 | 83.59 | -720,039.95 | -30,8% |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| Merck & Co., Inc. | 2,953,894 | 23,676,196 | 100.00 |
| SIMPLEX TRADING, LLC | 100 | 1,028 | 0.00 |